# Evotec SE American (EVO) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $1.86, market value $661 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Evotec SE American reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 0.8×**. Each dollar of revenue is priced at 0.8×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 0.9×**. The shares trade below book value, which can signal a bargain or a balance sheet the market doubts.
- **Free-cash-flow yield: -30.5%** (5-yr avg -5.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Gross margin: 10.5%**. Evotec SE American keeps 10.5% of revenue after the direct cost of what it sells, a thin margin typical of retail, distribution and commodity businesses.
- **Operating margin: -20.0%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -13.1%**. The company reported a net loss over the last twelve months.
- **Return on equity: -12.7%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -17.9%**. Return on all capital, debt included, is -17.9%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -11.5%**. Each dollar of assets produces -11.5% of profit.

## Growth
- **Revenue growth (1 yr): -1.1%** (3-yr 1.6%/yr, 5-yr 9.5%/yr). Revenue fell 1.1% over the last year, against 9.5% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 73.9%**. Earnings per share rose 73.9%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.55**. Debt is 0.55 times equity, moderate leverage.
- **Net debt / EBITDA: 0.1×**. It would take 0.1 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: -12.3×**. Operating profit covers interest only -12.3×: fragile.
- **Current ratio: 2.07** (quick 1.99). Current assets cover the next year's liabilities 2.07 times.
- **Altman Z-score: 1.73**. A Z-score of 1.73 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Evotec SE American does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -44.8%** (YTD -39.6%, 3-mo -33.6%). The shares are down 44.8% over twelve months including dividends.
- **From 52-week high: -56.4%** (3.3% above the low). Trading 56% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 40**. An RSI of 40 is neutral.
- **Beta (1 yr): 1.54** (volatility 55%). Beta of 1.54 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=EVO · Page: https://foliofundamentals.com/stocks/evo

Not investment advice.